Name
RF5-02 (Span): Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts - Commentary by: Fernando Petracci, MD, MSc, PhD
Date & Time
Thursday, December 4, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL